Expertise in
17
conditions

Dr. Zaid S. Al-Kadhimi

Hematology
Fred & Pamela Buffett Cancer Center-Nebraska Medical Center
505 S 45th St, 
Omaha, NE 
Accepting New Patients
29 Years of Experience
Expertise in
17
conditions
Fred & Pamela Buffett Cancer Center-Nebraska Medical Center
505 S 45th St, 
Omaha, NE 

Overview

Zaid Al-Kadhimi is a Hematologist practicing medicine in Omaha, Nebraska. He has been practicing medicine for over 29 years.

Dr. Al-Kadhimi is highly rated in 17 conditions, according to our data. His clinical expertise encompasses Acute Myeloid Leukemia (AML), Graft Versus Host Disease (GvHD), Myelodysplastic Syndrome (MDS), Bone Marrow Transplant, and Bone Marrow Aspiration.

He is actively involved in clinical research, co-authoring 41 peer reviewed articles and participating in 8 clinical trials. Dr. Al-Kadhimi is currently accepting new patients.

Specialties

Hematology

Licenses

Internal Medicine in MI

Hospital Affiliations

University Of Alabama Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Magnolia Health
  • HMO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
VIVA Health
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 7 Less Insurance Carriers -

Locations

Fred & Pamela Buffett Cancer Center-Nebraska Medical Center
505 S 45th St, Omaha, NE 68198
Other Locations
UAB Highlands
1201 11th Ave S, Birmingham, AL 35205

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation (BMT CTN 1702)
Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation (BMT CTN 1702)
Enrollment Status: Completed
Publish Date: January 05, 2026
Intervention Type: Other
Study Phase: Not Applicable
A Phase II Randomized, Placebo-Controlled, Multicenter Trial to Evaluate Protective Function of an Optimized Dose of CMVPepVax in Recipients of an Allogeneic Hematopoietic Stem Cell Transplant
A Phase II Randomized, Placebo-Controlled, Multicenter Trial to Evaluate Protective Function of an Optimized Dose of CMVPepVax in Recipients of an Allogeneic Hematopoietic Stem Cell Transplant
Enrollment Status: Completed
Publish Date: March 03, 2025
Intervention Type: Biological, Other
Study Drug: Multi-Peptide CMV-Modified Ankara Vaccine
Study Phase: Phase 2
A Phase II Study of Enhancing Anti-Tetanus Vaccine Response After Autologous Stem Cell Transplantation
A Phase II Study of Enhancing Anti-Tetanus Vaccine Response After Autologous Stem Cell Transplantation
Enrollment Status: Terminated
Publish Date: March 12, 2024
Intervention Type: Biological, Drug, Procedure
Study Drugs: Melphalan, T Cell-Depleted Hematopoietic Stem Cell Transplantation, Tetanus Toxoid Vaccine
Study Phase: Phase 2
Phase II Multicenter Study Of Natalizumab Plus Standard Steroid Treatment For High Risk Acute Graft-Versus-Host Disease
Phase II Multicenter Study Of Natalizumab Plus Standard Steroid Treatment For High Risk Acute Graft-Versus-Host Disease
Enrollment Status: Completed
Publish Date: October 21, 2022
Intervention Type: Drug
Study Drugs: Natalizumab, Steroids
Study Phase: Phase 2
A Phase 1/2 Dose Escalation Study Evaluating Safety and Feasibility of BPX-501 T Cells After Partially Mismatched, Related, T Cell-Depleted HSCT (Hematopoietic Stem Cell Transplant)
A Phase 1/2 Dose Escalation Study Evaluating Safety and Feasibility of BPX-501 T Cells After Partially Mismatched, Related, T Cell-Depleted HSCT (Hematopoietic Stem Cell Transplant)
Enrollment Status: Active_not_recruiting
Publish Date: July 12, 2022
Intervention Type: Biological, Drug, Procedure
Study Drugs: BPX-501, Rimiducid
Study Phase: Phase 1/Phase 2
Adjuvant Low Dose Rituximab for Acquired TTP With Severe ADAMTS13 Deficiency
Adjuvant Low Dose Rituximab for Acquired TTP With Severe ADAMTS13 Deficiency
Enrollment Status: Completed
Publish Date: August 17, 2021
Intervention Type: Biological
Study Phase: Phase 2
A Phase I/II Study of the Combination of Pembrolizumab and Lenalidomide, in Patients With Relapsed Non-Hodgkin and Hodgkin Lymphoma
A Phase I/II Study of the Combination of Pembrolizumab and Lenalidomide, in Patients With Relapsed Non-Hodgkin and Hodgkin Lymphoma
Enrollment Status: Terminated
Publish Date: August 14, 2020
Intervention Type: Biological, Drug
Study Phase: Phase 1/Phase 2
A Phase I Study of Mesenchymal Stromal Cells to Promote Stem Cell Engraftment in Patients With Severe Sickle Cell Disease Undergoing Haploidentical Hematopoietic Cell Transplantation
A Phase I Study of Mesenchymal Stromal Cells to Promote Stem Cell Engraftment in Patients With Severe Sickle Cell Disease Undergoing Haploidentical Hematopoietic Cell Transplantation
Enrollment Status: Withdrawn
Publish Date: November 07, 2018
Intervention Type: Biological
Study Phase: Phase 1
View 7 Less Clinical Trials

41 Total Publications

Randomized Phase III SIERRA Trial of 131I-Apamistamab Before Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care for Relapsed/Refractory AML.
Randomized Phase III SIERRA Trial of 131I-Apamistamab Before Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care for Relapsed/Refractory AML.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: September 19, 2024
Similar Doctors
Expertise in
34
conditions
Dr. Julie M. Vose
Hematology | Oncology
Expertise in
34
conditions
Dr. Julie M. Vose
Hematology | Oncology
Referral may be required

Fred & Pamela Buffett Cancer Center - Nebraska Medical Center

505 S 45th St., 
Omaha, NE 
 (0.1 miles away)
402-559-5600
Languages Spoken:
English, American Sign Language
See accepted insurances
Accepting New Patients
Offers Telehealth

Julie Vose is a Hematologist and an Oncologist practicing medicine in Omaha, Nebraska. Dr. Vose is highly rated in 34 conditions, according to our data. Her clinical expertise encompasses Non-Hodgkin Lymphoma, Peripheral T-Cell Lymphoma, Mantle Cell Lymphoma (MCL), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Vose is currently accepting new patients.

Expertise in
37
conditions
Expertise in
37
conditions
Referral may be required

Fred & Pamela Buffett Cancer Center - Nebraska Medical Center

505 S 45th St., 
Omaha, NE 
 (0.1 miles away)
402-559-5600
Languages Spoken:
English, American Sign Language
See accepted insurances
Accepting New Patients
Offers Telehealth

Matthew Lunning is a Hematologist practicing medicine in Omaha, Nebraska. Dr. Lunning is highly rated in 37 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, B-Cell Lymphoma, T-Cell Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Lunning is currently accepting new patients.

Expertise in
23
conditions
Dr. Vijaya R. Bhatt
Hematology | Oncology
Expertise in
23
conditions
Dr. Vijaya R. Bhatt
Hematology | Oncology
Referral may be required

Fred & Pamela Buffett Cancer Center - Bellevue Health Center

2510 Bellevue Medical Center Drive, Suite 250, 
Bellevue, NE 
 (8.3 miles away)
402-559-5600
Languages Spoken:
English, American Sign Language
See accepted insurances
Accepting New Patients
Offers Telehealth

Vijaya Bhatt is a Hematologist and an Oncologist practicing medicine in Bellevue, Nebraska. Dr. Bhatt is highly rated in 23 conditions, according to our data. His clinical expertise encompasses Acute Myeloid Leukemia (AML), Leukemia, Graft Versus Host Disease (GvHD), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Bhatt is currently accepting new patients.

Frequently Asked Questions about Dr. Zaid S. Al-Kadhimi

How do I make an appointment with Dr. Zaid S. Al-Kadhimi?

You can book an appointment with Dr. Zaid S. Al-Kadhimi by calling their office at 402-559-5600. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Zaid S. Al-Kadhimi a top-rated expert for Acute Myeloid Leukemia (AML)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Zaid S. Al-Kadhimi is classified as an Distinguished expert for Acute Myeloid Leukemia (AML), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Zaid S. Al-Kadhimi specialize in?

While Dr. Zaid S. Al-Kadhimi is a Hematology, they have specific expertise in Acute Myeloid Leukemia (AML), Bone Marrow Transplant, and Graft Versus Host Disease (GvHD). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Zaid S. Al-Kadhimi participate in research or clinical trials?

Yes. Dr. Zaid S. Al-Kadhimi has published 41 articles and abstracts on conditions like Acute Myeloid Leukemia (AML). You can view a list of Dr. Zaid S. Al-Kadhimi's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Zaid S. Al-Kadhimi accept my insurance?

Dr. Zaid S. Al-Kadhimi accepts most major insurance plans, including Anthem BCBS and Blue Cross Blue Shield. We recommend calling the office directly at 402-559-5600 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Al-Kadhimi's expertise for a condition
ConditionClose
    View All 12 Advanced Conditions
    View All 24 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile